Gate Bioscience, a biotechnology company developing a new class of small molecule medicines aiming to eliminate disease-causing proteins at their source, has announced the close of a US$65 million oversubscribed Series B financing. The Series B was led by new investor Forbion and was joined by additional new investor Eli Lilly and Company, as well as existing investors Versant Ventures, Andreessen Horowitz (a16z) Bio + Health, GV, and ARCH Venture Partners.
Latham & Watkins LLP represented Gate Bioscience in the funding round with an Emerging Companies & Growth team led by Bay Area partner Kathleen Wells, with associates Christopher Pham and Jack McKay, and assistance from Wes Dantzler.
